<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="77320">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02021045</url>
  </required_header>
  <id_info>
    <org_study_id>1706/2013</org_study_id>
    <nct_id>NCT02021045</nct_id>
  </id_info>
  <brief_title>Cerebral Microembolism During Hemodialysis</brief_title>
  <official_title>Quality and Distribution Pattern of Cerebral Microembolic Events During Hemodialysis - a Transcranial Doppler Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Medical University of Vienna</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Medical University of Vienna</source>
  <oversight_info>
    <authority>Austria: Ethikkommission</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is increasing evidence that renal replacement therapy (= continuous veno-venous
      hemodialysis) generates cerebral microembolism which is detectable on transcranial Doppler
      ultrasound.

      The aim of this study is to monitor patients with transcranial Doppler under two conditions:
      during hemodialysis and in a hemodialysis-free interval (in each period cerebral embolic
      load is detected during 30 minutes).

      The study hypothesis is that during hemodialysis the cerebral embolic load is significantly
      higher than in the hemodialysis-free interval.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">February 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>Cerebral embolic load</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Cerebral embolic load is measured in a 30 minutes-interval during hemodialysis and in a hemodialysis-free interval.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of cerebral embolic load</measure>
    <time_frame>30 minutes</time_frame>
    <safety_issue>No</safety_issue>
    <description>Quality of cerebral embolic load (solid vs. gaseous) is measured in a 30 minutes-interval during hemodialysis and in a hemodialysis-free interval.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Complication of Dialysis</condition>
  <condition>Thrombus Due to Renal Dialysis Device, Implant, or Graft</condition>
  <condition>Cerebral Embolism</condition>
  <arm_group>
    <arm_group_label>Patient on Hemodialysis</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Renal hemodialysis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Patient in a hemodialysis-free interval</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No Renal hemodialysis</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Renal hemodialysis (Fresenius 2008K, Bad Homburg, Germany)</intervention_name>
    <description>Renal replacement therapy is frequently used in patients with renal failure in order to eliminate substances obligatory excreted by the urine.</description>
    <arm_group_label>Patient on Hemodialysis</arm_group_label>
    <other_name>Continuous veno-venous hemodialysis</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Renal replacement therapy

          -  Age &gt; 18yrs.

        Exclusion Criteria:

          -  Inclusion in an other clinical study

          -  Gravidity

          -  Cerebral disease of any cause (e.g. intracerebral hemorrhage, stroke)

          -  Sepsis and related conditions affecting the brain (septic cerebral embolism)

          -  Allergy against materials of the medical device used in the study (transcranial
             Doppler)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gabor Erdoes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Medical University of Vienna</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Gabor Erdoes, MD</last_name>
    <phone>+43 (0) 1 40400 - 4102</phone>
    <email>erdoesgabor@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ulrich Klein, MD</last_name>
    <phone>+43 (0) 1 40400 - 4102</phone>
    <email>ulrich.klein@meduniwien.ac.at</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Medical University of Vienna</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gabor Erdoes, MD</last_name>
      <phone>+43 (0) 1 40400 - 4102</phone>
      <email>erdoesgabor@gmail.com</email>
    </contact>
    <contact_backup>
      <last_name>Klaus Markstaller, MD, PhD</last_name>
      <phone>+43 (0) 1 40400 - 4102</phone>
      <email>klaus.markstaller@meduniwien.ac.at</email>
    </contact_backup>
    <investigator>
      <last_name>Gabor Erdoes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Austria</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 19, 2013</lastchanged_date>
  <firstreceived_date>November 20, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Medical University of Vienna</investigator_affiliation>
    <investigator_full_name>Dr. Gabor Erdoes</investigator_full_name>
    <investigator_title>Dr Gabor Erdoes</investigator_title>
  </responsible_party>
  <is_fda_regulated>No</is_fda_regulated>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Intracranial Embolism</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
